Get started
Author

Olivier Bylicki

Observed names: Bylicki, O., O. BYLICKI, O. Bylicki, Oliver Bylicki
OpenAlex ID: A5041980592
Nonoperative Management of Squamous-Cell Carcinoma of the Rectum
2014 · Julien Péron, Olivier Bylicki, et al. · Diseases of the Colon & Rectum · 38
1035P A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017)
2022 · C. Decroisette, I. Monnet, et al. · Annals of Oncology · 9
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis
2025 · Antoine Bronstein, Hubert Curcio, et al. · Clinical Lung Cancer · 4
223MO Five-year outcomes of participants with pathological complete response (pCR) enrolled in the KEYNOTE-671 trial of perioperative pembrolizumab (pembro) in early-stage NSCLC
2026 · M. Majem, M.C. Garassino, et al. · ESMO Open · 3
PDF
LBA58_PR Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.
2017 · Zalcman, G., Mazieres, J., et al. · HAL (Le Centre pour la Communication Scientifique Directe) · 3
962P Quality of life at diagnosis for unresectable stage III NSCLC: Initial results from the national prospective study OBSTINATE (GFPC 06-2019)
2022 · C. Ricordel, A. Anota, et al. · Annals of Oncology · 1
1097P Impact of tumor and liquid rebiopsy in metastatic non-small cell lung cancer with EGFR/ALK/ROS oncogenic drivers, progressing after optimal target therapy
2022 · A. Bronstein, R. Gervais, et al. · Annals of Oncology · 1
PDF
Corrigendum to “LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671”
2026 · H. Wakelee, J. Spicer, et al. · Annals of Oncology
PDF
99P Outcomes of synchronous oligometastatic NSCLC treated with (chemo)-immunotherapy: From the French ESME lung database
2026 · B. Courtier, M. Chevrier, et al. · ESMO Open
LBA9 Perioperative pembrolizumab in early-stage non–small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup
2025 · M. Tsuboi, H. Wakelee, et al. · Annals of Oncology
P2.06.43 Estimating Tumour Microenvironment Cellular States From Bulk RNAseq Produces Biomarkers of Clinical Outcome Across Stages
2025 · M. Hurtado, E. Gobbini, et al. · Journal of Thoracic Oncology
EP12.64 Real-World Effectiveness of First-Line Osimertinib in EGFR-Mutated NSCLC: Interim Results From the French POSITHES Study
2025 · J-B. Aulia, A. Bizieux, et al. · Journal of Thoracic Oncology
1872P Stop or continue immune checkpoint inhibitors at 2 years for advanced-stage NSCLC? Retrospective analysis of the therapeutic strategy of two academic centers
2025 · A. De Gunten, A. Mogenet, et al. · Annals of Oncology
2007P Tolerance and efficacy of targeted therapies after immunotherapy in metastatic non-small cell lung cancer with molecular alterations: TOXIMAD GFPC 04-2022 study
2025 · T. Pierret, J.B. Auliac, et al. · Annals of Oncology
1899P Predicting the efficacy of immunotherapy in advanced NSCLC: Are clinical scores really useful?
2025 · J. Ancel, O. Bylicki, et al. · Annals of Oncology
2969P Long-term real-life outcomes of nivolumab-ipilimumab combination in untreated patients with unresectable pleural mesothelioma update of MESOIMMUNE: GFPC 04-2021 study
2025 · L. Greillier, F. Guisier, et al. · Annals of Oncology
LBA76 Paclitaxel-bevacizumab ± atezolizumab in advanced non-squamous NSCLC progressing after chemo-immunotherapy: IFCT-2201 ADAPTABLE randomized phase II trial
2025 · A. Scherpereel, L. Greillier, et al. · Annals of Oncology
PDF
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018)
2025 · Romain Corre, Chantal Decroisette, et al. · Clinical Lung Cancer
15P: Updated OS and final QoL and safety results of a randomised, open-label, phase III study comparing nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced NSCLC aged ≥70 years or with an ECOG PS of 2 (GFPC 08–2015 ENERGY)
2025 · H. Lena, L. Greillier, et al. · Journal of Thoracic Oncology
PDF
226P: Real-world patient characteristics and TREAtment patterns for stage III in NSCLC in FRance: TREAP
2025 · C. Chouaid, O. Bylicki, et al. · Journal of Thoracic Oncology
PDF
SMART : étude rétrospective multicentrique des caractéristiques et de la réponse aux traitements des cancers pulmonaire SMARCA4 déficients
2025 · I. Duparc, M. Grecea, et al. · Revue des Maladies Respiratoires Actualités
Efficacité et tolérance de l’amivantamab dans le cadre de l’accès précoce pour les patients atteints d’un CBNPC métastatique avec mutation type insertion dans l’exon 20 de l’EGFR : Amexon 20 GFPC 02-2022
2025 · T. Pierret, F. Guisier, et al. · Revue des Maladies Respiratoires Actualités
Tolérance et efficacité des thérapies ciblées en post immunothérapie dans les cancers bronchiques non à petites cellules métastatiques avec altérations moléculaires. Étude TOXIMAD GFPC 04-2022
2025 · T. Pierret, J.B. Auliac, et al. · Revue des Maladies Respiratoires Actualités
Le retour au travail des militaires français après un cancer
2024 · G. VANDERPERRE, M. LALANDE, et al. · Revue Médecine et Armées
1368P Correlation between depth of response at 6 months and survival in patients (pts) with metastatic non-small cell lung carcinoma (mNSCLC): SPORE trial
2024 · F. Moinard-Butot, J-B. Barbe-Richaud, et al. · Annals of Oncology
PDF
Works count: 29
Citation count: 59
H-index: 3
I10-index: 1
Year
Topic
Type